VUGENE is partnering with leading Contract Research Organization (CRO) Inotiv, Inc. (NASDAQ: NOTV) in a new strategic collaboration.
The collaboration is designed to accelerate AI-assisted drug discovery and enhance data-driven insights across the drug development continuum. For VUGENE it represents an important entry into the Pharmaceutical Services market.
Through this partnership, Inotiv will integrate VUGENE’s cloud-based bioinformatics and computational platform into its Discovery & Translational Sciences Division, enabling a more efficient and intelligent analysis of complex biological data. The collaboration will enhance Inotiv’s ability to interpret the full spectrum of epigenomic, proteomic, and other molecular datasets, with the goal of ultimately improving the prediction of drug efficacy and safety in early-stage research.
Juozas Gordevičius, PhD, Founder and CTO of VUGENE, commented: “Inotiv’s integrated approach to drug discovery, specifically their focus on the qualification of new target biology and disease modelling, makes them an ideal partner as we expand further into the Pharmaceutical Services market. Together we can combine advanced multi-omics, bioinformatics and AI with experimental expertise to accelerate scientific breakthroughs and improve human health.”
Scott Daniels, PhD, Senior Vice President of Drug Discovery & Translational Sciences at Inotiv, said: “To maximize the value of our clients’ discovery programs, we must efficiently integrate and interpret complex datasets. VUGENE’s AI-enabled bioinformatics platform gives our team a powerful tool to advance data-driven, AI-assisted discovery, helping clients make faster, more informed decisions.”
Photo credits: Andrej Vasilenko
